The clinical outcomes and treatment responses of acute myeloid leukemia (AML) patients are heterogeneous. Here, the authors use bulk and single-cell sequencing approaches and identify two transcriptomic subtypes within NPM1-mutated AML with distinct immune evasion properties and responses to hematopoietic stem cell transplantation.
- Henrik Lilljebjörn
- Pablo Peña-Martínez
- Thoas Fioretos
